ImmuCell
Portland, ME, USAwww.immucell.com
Presenter: Michael Brigham, President and CEO
ImmuCell Corporation (NasdaqCM: ICCC) was founded in 1982 and completed an initial public offering of common stock in 1987. We are an animal health biotechnology company serving veterinarians and producers in the dairy and beef industries with innovative and proprietary products that improve animal health and productivity. After achieving approval from the USDA to sell First Defense® in 1991, we focused most of our efforts in the 1990’s on developing human product applications of the underlying milk antibody technology. Beginning in 1999, we re-focused on First Defense® and other products for the dairy industry.
Domestic product sales increased 3% in 2008. We have been operating without bank debt for over six years and have not had to dilute our shareholders by raising equity to fund our operations. Our principal product under development is Mast Out® (an intramammary infusion product containing Nisin) as an alternative to traditional antibiotics for the treatment of mastitis in lactating cows, subject to FDA Approval. The safety profile of Nisin may allow for the use of Mast Out® in the U.S. without milk discard or meat withhold requirements.